Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Enovis (ENOV)
NYSEHealth CareMedical - DevicesSnapshot 2026-11-04
$28.62+17.20%
Close 2026-11-05 · 1-day change
NYSEHealth CareMedical - DevicesSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
3.64 → 3.54 EPS · FY ending Dec 31, 2027 · 6 analysts
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
Change in the same fiscal period’s mean EPS estimate from Oct 5, 2026 to Nov 4, 2026: (new ÷ prior − 1). Contributor count changed from 6 to 6; this is not the number of analysts revising. The ±10% axis is a display range.
The EPS and P/E reference is not available for ENOV yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Adjusted EBITDA near $430 million | Profit rises with adjusted EBITDA near $430 million. | Broken | Adjusted EBITDA falls below $425 million in FY26 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 5, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earningsObserved price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
ENOV is a growth and execution story in the healthcare sector, with a cyclical risk component. Its 1-to-3-year thesis is intact, though the signal recently shifted from mildly favorable to mixed after an earnings miss.
The evidence describes ENOV as cheap versus peers, with low signs of fragility in what is priced in. The expectations gap is negative, but confidence in that valuation read is medium; the company is still loss-making, so valuation should be considered alongside execution risk.
Near-term results have been strong overall, with organic sales growth of 5% in the second quarter and 3% in the first, while reconstructive sales grew 6% to 11%. Management has reaffirmed 2026 revenue guidance of $2.31 billion to $2.37 billion and adjusted EBITDA guidance of $425 million to $435 million, but a recent earnings miss and a run of misses make the next update important.
The multi-year view depends on whether commercial execution and innovation can sustain growth while management delivers its revenue and profitability guidance. Near term, a guidance cut or further weakening in jobs data could weigh on cyclical healthcare names, while continued strong results and guidance from sector bellwethers could support the sector backdrop.
ENOV’s operating progress keeps the long-term thesis intact, but loss-making status, elevated risk, and mixed recent signals leave execution and guidance as key tests over the next 1 to 3 years. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| Innovation in orthopedics helps keep sales strong. |
| Improving |
| Innovation efforts stall or fail to advance orthopedics products |
Qualitative: 2 product advances (Spinamic, eCential) vs target of sustained innovation News highlights Spinamic launch and eCential robotics acquisition as key innovation drivers, offset by Q2 earnings miss and lowered price targets. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 3 of 3 supplied quarters. Management reported: ““Commercial execution is improving, our innovation pipeline continues to strengthen our competitive positioning, and our teams are demonstrating agility in navigating increasingly dynamic end markets.” “Our priorities - commercial execution and innovation, operational excellence, and financial discipline - position us well to navigate near-term uncertainty while continuing to invest in long-term growth.” Delivery assessment Nov 4, 2026 |
Revenue grows to about $2.34 billion | Enovis grows revenue about 5% a year to $2.34 billion in 2026. | Broken | Revenue falls below $2.31 billion in FY26 | Revenue: $582.782M FY2026-Q2; GAAP. Published target: ~$2.34 billion. Annual target cannot be compared with a quarterly or TTM observation. Aug 6, 2026582,782,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$4.08 → $3.54 · observed estimates
$2.47B → $2.45B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $4.08 | $2,465,816,420 | 12 / 12 |
| 2026-07-25 | $4.08 | $2,465,816,420 | 12 / 12 |
| 2026-07-26 | $4.08 | $2,465,816,420 | 12 / 12 |
| 2026-07-27 | $4.08 | $2,465,816,420 | 12 / 12 |
| 2026-07-28 | $4.08 | $2,466,010,081 | 6 / 8 |
| 2026-07-29 | $4.08 | $2,466,010,081 | 6 / 8 |
| 2026-07-30 | $4.08 | $2,465,922,670 | 13 / 13 |
| 2026-07-31 | $4.08 | $2,465,922,670 | 13 / 13 |
| 2026-08-01 | $4.08 | $2,466,101,438 | 7 / 9 |
| 2026-08-02 | $4.08 | $2,465,922,670 | 13 / 13 |
| 2026-08-03 | $4.08 | $2,465,922,670 | 13 / 13 |
| 2026-08-04 | $4.08 | $2,466,078,361 | 7 / 9 |
| 2026-08-05 | $4.08 | $2,465,922,670 | 13 / 13 |
| 2026-08-06 | $4.08 | $2,466,078,361 | 7 / 9 |
| 2026-08-07 | $4.07 | $2,464,061,914 | 7 / 9 |
| 2026-08-08 | $4.07 | $2,459,441,380 | 13 / 11 |
| 2026-08-09 | $4.07 | $2,459,441,380 | 13 / 11 |
| 2026-08-10 | $4.07 | $2,459,441,380 | 13 / 11 |
| 2026-08-11 | $4.07 | $2,464,061,914 | 7 / 9 |
| 2026-08-12 | $4.06 | $2,457,699,410 | 13 / 13 |
| 2026-08-13 | $4.06 | $2,457,699,410 | 13 / 13 |
| 2026-08-14 | $4.07 | $2,464,061,914 | 7 / 9 |
| 2026-08-15 | $4.07 | $2,464,061,914 | 7 / 9 |
| 2026-08-16 | $4.07 | $2,464,061,914 | 7 / 9 |
| 2026-08-17 | $4.07 | $2,464,061,914 | 7 / 9 |
| 2026-08-18 | $4.07 | $2,464,061,914 | 7 / 9 |
| 2026-08-19 | $4.07 | $2,464,061,914 | 7 / 9 |
| 2026-08-20 | $4.01 | $2,454,708,120 | 6 / 9 |
| 2026-08-21 | $4.01 | $2,454,708,120 | 6 / 9 |
| 2026-08-22 | $4.01 | $2,454,707,843 | 6 / 9 |
| 2026-08-23 | $4.01 | $2,453,784,766 | 6 / 9 |
| 2026-08-24 | $4.01 | $2,453,784,766 | 6 / 9 |
| 2026-08-25 | $4.01 | $2,453,784,766 | 6 / 9 |
| 2026-08-26 | $4.01 | $2,453,784,766 | 6 / 9 |
| 2026-08-27 | $4.01 | $2,453,784,766 | 6 / 9 |
| 2026-08-28 | $4.01 | $2,453,784,766 | 6 / 9 |
| 2026-08-29 | $4.01 | $2,453,784,766 | 6 / 9 |
| 2026-08-30 | $4.01 | $2,453,784,766 | 6 / 9 |
| 2026-08-31 | $4.01 | $2,453,784,766 | 6 / 9 |
| 2026-09-01 | $4.01 | $2,453,784,766 | 6 / 9 |
| 2026-09-02 | $4.01 | $2,453,784,766 | 6 / 9 |
| 2026-09-03 | $3.69 | $2,453,787,620 | 6 / 9 |
| 2026-09-04 | $3.69 | $2,453,787,620 | 6 / 9 |
| 2026-09-05 | $3.69 | $2,453,787,620 | 6 / 9 |
| 2026-09-06 | $3.69 | $2,453,787,620 | 6 / 9 |
| 2026-09-07 | $3.69 | $2,453,787,620 | 6 / 9 |
| 2026-09-08 | $3.69 | $2,453,787,620 | 6 / 9 |
| 2026-09-09 | $3.69 | $2,453,787,620 | 6 / 9 |
| 2026-09-10 | $3.69 | $2,454,172,235 | 6 / 9 |
| 2026-09-11 | $3.69 | $2,454,172,235 | 6 / 9 |
| 2026-09-12 | $3.69 | $2,454,172,235 | 6 / 9 |
| 2026-09-13 | $3.69 | $2,454,172,235 | 6 / 9 |
| 2026-09-14 | $3.69 | $2,454,172,235 | 6 / 9 |
| 2026-09-15 | $3.69 | $2,454,172,235 | 6 / 9 |
| 2026-09-16 | $3.69 | $2,454,172,235 | 6 / 9 |
| 2026-09-17 | $3.69 | $2,454,172,235 | 6 / 9 |
| 2026-09-18 | $3.69 | $2,454,172,235 | 6 / 9 |
| 2026-09-19 | $3.69 | $2,454,172,235 | 6 / 9 |
| 2026-09-20 | $3.69 | $2,454,172,235 | 6 / 9 |
| 2026-09-21 | $3.69 | $2,454,172,235 | 6 / 9 |
| 2026-09-22 | $3.69 | $2,454,172,235 | 6 / 9 |
| 2026-09-23 | $3.69 | $2,454,172,235 | 6 / 9 |
| 2026-09-24 | $3.69 | $2,454,172,235 | 6 / 9 |
| 2026-09-25 | $3.69 | $2,454,172,235 | 6 / 9 |
| 2026-09-26 | $3.69 | $2,454,172,235 | 6 / 9 |
| 2026-09-27 | $3.69 | $2,454,172,235 | 6 / 9 |
| 2026-09-28 | $3.69 | $2,454,172,235 | 6 / 9 |
| 2026-09-29 | $3.69 | $2,454,172,235 | 6 / 9 |
| 2026-09-30 | $3.69 | $2,454,172,235 | 6 / 9 |
| 2026-10-01 | $3.69 | $2,454,172,235 | 6 / 9 |
| 2026-10-02 | $3.69 | $2,454,172,235 | 6 / 9 |
| 2026-10-03 | $3.69 | $2,454,172,235 | 6 / 9 |
| 2026-10-04 | $3.64 | $2,453,313,250 | 6 / 9 |
| 2026-10-05 | $3.64 | $2,453,313,250 | 6 / 9 |
| 2026-10-06 | $3.59 | $2,453,697,866 | 6 / 9 |
| 2026-10-07 | $3.59 | $2,453,697,866 | 6 / 9 |
| 2026-10-08 | $3.59 | $2,453,697,866 | 6 / 9 |
| 2026-10-09 | $3.59 | $2,453,697,866 | 6 / 9 |
| 2026-10-10 | $3.59 | $2,453,697,866 | 6 / 9 |
| 2026-10-11 | $3.59 | $2,453,697,866 | 6 / 9 |
| 2026-10-12 | $3.59 | $2,453,697,866 | 6 / 9 |
| 2026-10-13 | $3.54 | $2,453,695,012 | 6 / 9 |
| 2026-10-14 | $3.54 | $2,453,695,012 | 6 / 9 |
| 2026-10-15 | $3.54 | $2,453,695,012 | 6 / 9 |
| 2026-10-16 | $3.54 | $2,453,695,012 | 6 / 9 |
| 2026-10-17 | $3.54 | $2,453,695,012 | 6 / 9 |
| 2026-10-18 | $3.54 | $2,453,695,012 | 6 / 9 |
| 2026-10-19 | $3.54 | $2,453,695,012 | 6 / 9 |
| 2026-10-20 | $3.54 | $2,453,695,012 | 6 / 9 |
| 2026-10-21 | $3.54 | $2,453,695,012 | 6 / 9 |
| 2026-10-22 | $3.54 | $2,453,695,012 | 6 / 9 |
| 2026-10-23 | $3.54 | $2,453,695,012 | 6 / 9 |
| 2026-10-24 | $3.54 | $2,453,695,012 | 6 / 9 |
| 2026-10-25 | $3.54 | $2,453,695,012 | 6 / 9 |
| 2026-10-26 | $3.54 | $2,453,695,012 | 6 / 9 |
| 2026-10-27 | $3.54 | $2,453,695,012 | 6 / 9 |
| 2026-10-28 | $3.54 | $2,453,695,012 | 6 / 9 |
| 2026-10-29 | $3.54 | $2,453,695,012 | 6 / 9 |
| 2026-10-30 | $3.54 | $2,453,695,012 | 6 / 9 |
| 2026-10-31 | $3.54 | $2,453,695,012 | 6 / 9 |
| 2026-11-01 | $3.54 | $2,453,695,012 | 6 / 9 |
| 2026-11-02 | $3.54 | $2,453,695,012 | 6 / 9 |
| 2026-11-03 | $3.54 | $2,453,695,012 | 6 / 9 |
| 2026-11-04 | $3.54 | $2,453,695,012 | 6 / 9 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 12 Buy / Strong Buy · 1 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 1 recorded
0 raises · 0 cuts · 0 unchanged · 1 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
2 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.